复杂患者的治疗：强调尼古丁-猫眼课题宝

复杂患者的治疗：强调尼古丁

批准号：

7525009

负责人：

Sharon M. Hall

金额：

$11.37万

依托单位：

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

依托单位国家：

美国

项目类别：

财政年份：

2003

资助国家：

美国

项目状态：

已结题

起止时间：

2003-08-20 至 2013-06-30

来源：

https://reporter.nih.gov/project-details/7525009

关键词：

Abstinence Accident and Emergency department Acute Address Adherence Adult Adverse effects Advertisements Advisory Committees Age Age-Years Aging Agreement Air Alcohol consumption Ambulatory Care Facilities American American Lung Association Anabasine Anger Antidepressive Agents Anxiety Applications Grants Area Attention Award Back Beck depression inventory Beds Behavior Therapy Behavioral Behavioral Model Belief Biological Assay Biostatistics Core Blood Pressure Blood Pressure Monitors Body Weight Changes Boxing Budgets Build-it Bupropion Bupropion/Nicotine Caloric Restriction Carbon Monoxide Caring Case Management Case Manager Case Study Caucasians Caucasoid Race Cells Cessation Research Characteristics Chronic Chronic Disease Cigarette Cigarette Smoker Cities Client Clinic Clinical Clinical Trials Code Cognitive Collaborations Combined Modality Therapy Commit Communicable Diseases Communication Communities Comorbidity Complex Condition Conflict (Psychology)Consultations Controlled Clinical Trials Cost Control Cost Effectiveness Analysis Cotinine Counseling Data Data Analyses Data Collection Data Set Databases Decision Making Dependence Depressed mood Depressive disorder Development Diagnosis Direct Costs Disease Dose Double-Blind Method Drops Drug Abuse Treatment Services Drug abuse Drug usage Economics Educational Materials Effectiveness Effectiveness of Interventions Elderly Electronics Elements Emergency Situation Employment Status Enrollment Ensure Equation Equilibrium Equipment and supply inventories Estrogens Evaluation Event Exercise Expert Systems Faculty Family Feedback Frail Elderly Funding Future Gender General Population Genetic Geriatric Psychiatry Goals Grant Gray unit of radiation dose Group Therapy Guidelines HIV HIV Seropositivity Health Health Benefit Health Care Costs Health Personnel Health Services Health Services Accessibility Health Services Research Health Status Health system Healthcare Healthcare Systems Hospitals Hour Human Incentives Incidence Income Individual Injecting drug user Institutes Instruction Intake Intervention Intervention Studies Interview Lead Leadership Learning Left Legal Legal Status Length Letters Life Literature Lobbying Logistic Regressions Longitudinal Studies Mails Maintenance Manuals Manufacturer Name Measurement Measures Medical Medical Staff Medication Management Mental Depression Mental Health Mental disorders Mentally Ill Persons Mentors Methadone Methodology Methods Minimal Contact Treatment Modality Modeling Moderate Exercise Modification Monitor Mood Disorders Moods Motivation Movement National Institute of Drug Abuse Nature Newspapers Nicotine Nicotine Dependence Nortriptyline Not Otherwise Specified Numbers Nursing Homes Opiates Opioid Other Therapy Outcome Outcome Measure Outpatients Pamphlets Paper Participant Pathway interactions Patient Self-Report Patients Pattern Perception Personal Satisfaction Pharmaceutical Preparations Pharmacological Treatment Pharmacotherapy Phase Physical Function Physical activity Pilot Projects Placebo Control Placebos Placement Population Practice Guidelines Preparation Prevalence Prevention intervention Prevention therapy Principal Investigator Probability Procedures Process Production Professional counselor Protocols documentation Provider Psyche structure Psychiatric Diagnosis Psychiatric therapeutic procedure Psychiatrist Psychological reinforcement Psychometrics Psychosocial Assessment and Care Public Health Public Sector Published Comment Published Practice Guidelines Publishing Purpose Questionnaires Randomized Randomized Clinical Trials Rate Readiness Recommendation Recording of previous events Recruitment Activity Recurrent disease Recycling Regression Analysis Relapse Reporting Research Research Design Research Personnel Research Training Resources Restart Retirement Risk Role SF-36 Sample Size Sampling San Francisco Schedule Scientist Score Self-Administered Series Serum Services Severities Sex Functioning Shapes Site Smoke Smoker Smoking Smoking Behavior Smoking Cessation Intervention Smoking Status Social Functioning Social Network Social Work Social status Social support Source Staging Standards of Weights and Measures Statistical Methods Stratification Stress Study models Substance Use Disorder Substance abuse problem Suggestion Supervision Supported Employment Surgeon System TNFRSF5 gene Target Populations Technology Telephone Testing Therapeutic Thinking Time Titrations Tobacco Dependence Tobacco smoking Today Training Training Programs Training Support Transportation Travel Treatment Efficacy Treatment outcome Treatment/Psychosocial Effects Universities Vision Visit Week Weight Gain Weight maintenance regimen Withdrawal Withdrawal Symptom Withholding Treatment Woman Work Writing Zyban addiction age group aged anatabine base behavior change blind care systems cigarette smoking clinical efficacy computerized concept contingency management coping cost cost effectiveness data management day deep breathing exercises demographics depressive symptoms design disorder later incidence prevention dissemination research disturbance in affect drug abstinence drug abuser dysphoria early /brief intervention /therapy expectation experience follow-up functional disability geriatric depression group counseling health care service utilization human PTCH2 protein improved indexing innovation instrument interest loss of function male medication compliance member men monitoring device mortality motivational enhancement therapy neglect nicotine gum nicotine patch nicotine replacement non-smoker non-smoking older women outreach pill post-doctoral training prevent programs psychologic psychosocial reinforced behavior research study response restraint self help sex skills smoking cessation smoking intervention social social group stressor substance abuser therapy design therapy development treatment program voucher wound

中文摘要

翻译

描述（由申请人提供）：这个竞争性更新K05提案的目标是继续支持我在尼古丁依赖治疗方面的研究，进一步提高我指导初级科学家和培养博士后学者的能力，使我能够通过研究中心的管理继续担任科学领导，并将研究成果传播给科学和临床界。自从上次提交这个奖项以来，我已经发表、出版或审稿了62篇科学论文。我完成了一项临床试验（N=322），对精神科门诊的抑郁吸烟者进行了创新干预，研究了戒烟及其对心理健康的影响，以及干预的成本效益。根据建议，我正在完成两项主要的临床试验：(1)长期吸烟者行为复发预防和安非他酮治疗的研究（N=407）；(2)针对老年吸烟者的延长、年龄特异性复发预防和尼古丁替代治疗的研究（n=403）。在这两项研究中，延长治疗条件已经产生了生物学上证实的戒断率，一年从53%到42%。最重要的是，这些比率在两年的随访中没有变化；它们恰好保持在一年观察到的水平。我继续指导一个P50中心的拨款，重点是治疗以尼古丁为重点的复杂病人。此外，我还与其他科学家合作，他们大多是我的徒弟。这项工作包括针对目标人群和共病吸烟者的烟草依赖治疗研究。此外，我还与其他科学家合作，研究吸烟者对安非他酮的基因反应，以及减少尼古丁香烟的影响。如果这个奖项得到资助，我将继续我在扩展治疗方面的工作，研究在卫生保健环境中的实施，并开发和测试基于它的适应技术。我将继续在P50资助和博士后培训资助中担任领导角色，并将继续与其他教师，特别是初级教师合作。在获得这个奖项之前，我就有指导初级教员的历史。我也将继续我的指导角色，并增加我对初级教师的指导，随着新教师的招募，以及新的部门指导计划的实施和加强。最后，我将继续与博士后学员个人一起工作。

英文摘要

DESCRIPTION (provided by applicant): The goal of this competing renewal K05 proposal is to continue to support my research in the treatment of nicotine dependence, to further my capacity to mentor junior scientists and train postdoctoral scholars, to allow me to continue in scientific leadership through research center administration, and to disseminate research findings to the scientific and clinical community. Since this award was last submitted, I have published, in press, or under review 62 scientific papers. I completed a clinical trial (N=322) of an innovative intervention for depressed smokers in a psychiatric outpatient clinic, studying both smoking abstinence and its impact on mental health, and the cost-effectiveness of the intervention. As proposed, I am completing two major clinical trials: (1) a study of extended behavioral relapse prevention and bupropion treatment for chronic smokers (N=407); (2) a study of extended, age-specific relapse prevention and nicotine replacement treatment for older smokers (n=403). Extended treatment conditions in these two studies have produced biologically confirmed abstinence rates from 53 to 42% at one year. Of greatest importance, these rates do not change at two year follow-up; they remain at precisely the level observed at one year. I continued to direct a P50 center grant that focuses on Treatment of Complex Patients with an emphasis on nicotine. In addition, I have developed collaborations with other scientists, who are mostly my mentees. This work includes tobacco dependence treatment studies for targeted populations and for co-morbid smokers. In addition, I collaborate with other scientists of the genetics of bupropion response in smokers, and on the effects of reduced nicotine cigarettes. If this award is funded, I will continue my work on extended treatment, studying implementation in health care settings, and developing and testing technology based adaptations of it. I will continue my leadership role in the P50 grant and in the postdoctoral training grant, and will continue to collaborate with other faculty, especially junior faculty. I have a history of mentoring junior faculty that extends back well before the receipt of this award. I will also continue my mentoring role, and increase my mentoring of junior faculty, as new faculty are recruited, and the new departmental mentoring program is implemented and enhanced. Last, I will continue my work with individual postdoctoral trainees.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文